Ivermectin interacts with human ABCG2

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 94-97

  Jani, Márton ^a   Makai, Ildikó ^a   Kis, Emese ^a   Szabó, Pál ^b   Nagy, Tünde ^a   Krajcsi, Péter ^a   Lespine, Anne ^c  

^a SOLVO BIOTECHNOLOGY   (Hungary)

^b CHEMICAL RESEARCH CENTER   (Hungary)

^c CEMAGREF   (France)

Author keywords

ABC transporter; ADME; BCRP; Macrocyclic lactones; Toxicity

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IVERMECTIN;

ARTICLE; CELL ASSAY; DRUG INHIBITION; IC 50; MEMBRANE PERMEABILITY;

EID: 78650059823     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22262     Document Type: Article

References (24)

1. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR. 1999. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27: 581-587.
2. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Riele HP, Berns AJ, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502.
3. Lespine A, Dupuy J, Alvinerie M, Comera C, Nagy T, Krajcsi P, Orlowski S. 2009. Interaction of macrocyclic lactones with the multidrug transporters: The bases of the pharmacokinetics of lipid-like drugs. Curr Drug Metab 10: 272-288.
4. Gonzalez-Canga A, Fernandez-Martinez N, Sahagun-Prieto A, Diez-Liebana MJ, Sierra-Vega M, Garcia-Vieitez JJ. 2009. A review of the pharmacological interactions of ivermectin in several animal species. Curr Drug Metab 10: 359-368.
5. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. 1998. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 28: 313-321.
6. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705.
7. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M. 2006. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact 159: 169-179.
8. Kiki-Mvouaka S, Menez C, Borin C, Lyazrhi F, Foucaud-Vignault M, Dupuy J, Collet X, Alvinerie M, Lespine A. 2010. Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin and moxidectin in mice. Drug Metab Dispos 38: 573-580.
9. El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. 2008. The effect of azithromycin on ivermectin pharmacokinetics-A population pharmacokinetic model analysis. PLoS Negl Trop Dis 2: e236.
10. Sarkadi B, Homolya L, Szakacs G, Varadi A. 2006. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.
11. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. 2008. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36: 995-1002.
12. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. 2006. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3: 55-61.
13. Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH. 2009. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 15: 3084-3093.
14. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB. 2008. Breast cancer resistance protein (ABCG2) and drug disposition: Intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 18: 439-448.
15. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y. 2008. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84: 95-103.
16. Merino G, Real R, Baro MF, Gonzalez-Lobato L, Prieto JG, Alvarez AI, Marques MM. 2009. Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: Increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors. Drug Metab Dispos 37: 5-9.
17. Muenster U, Grieshop B, Ickenroth K, Gnoth MJ. 2008. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25: 2320-2326.
18. Geyer J, Gavrilova O, Petzinger E. 2009. Brain penetration of ivermectin and selamectin in mdr1a, b P-glycoprotein- and bcrp-deficient knockout mice. J Vet Pharmacol Ther 32: 87-96.
19. Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P. 2009. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: Implications for drug resistance. Ann Rheum Dis 68: 1201-1207.
20. von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. 2009. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmakol 379: 11-26.
21. Glavinas H, Kis E, Pal A, Kovacs R, Jani M, Vagi E, Molnar E, Bansaghi S, Kele Z, Janaky T, Bathori G, von Richter O, Koomen GJ, Krajcsi P. 2007. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: A useful tool to detect drug-transporter interactions. Drug Metab Dispos 35: 1533-1542.
22. Lespine A, Martin S, Dupuy J, Roulet A, Pineau T, Orlowski S, Alvinerie M. 2007. Interaction of macrocyclic lactones with P-glycoprotein: Structure-affinity relationship. Eur J Pharm Sci 30: 84-94.
23. Margolis JM, Obach RS. 2003. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31: 606-611.
24. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27: 1350-1359.